• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Chemours Company

    5/6/26 7:00:30 AM ET
    $CC
    Major Chemicals
    Industrials
    Get the next $CC alert in real time by email
    S-8 1 cc-20260505.htm S-8 S-8

     

     

    As filed with the U.S. Securities and Exchange Commission on May 6, 2026.

     

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    The Chemours Company

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

     

    46-4845564

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

     

     

    1007 Market Street

     

     

    Wilmington, Delaware

     

    19801

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    THE CHEMOURS COMPANY 2026 EQUITY AND INCENTIVE PLAN

    (Full title of the plan)

     

    Kristine M. Wellman

    Senior Vice President, General Counsel and Corporate Secretary

    The Chemours Company

    1007 Market Street, Wilmington, Delaware 19801

    (302) 773-1000

    (Name and address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    David M. Lynn

    Jonathan Burr

    Goodwin Procter LLP

    1900 N Street, NW

    Washington, D.C. 20036

    (202) 346-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

     

    ☒

     

    Accelerated filer

     

    ☐

     

     

     

     

    Non-accelerated filer

     

    ☐

     

    Smaller reporting company

     

    ☐

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering 6,375,275 shares of common stock, par value $0.01 per share (the “Common Stock”), of The Chemours Company (the “Company”) issuable pursuant to The Chemours Company 2026 Equity and Incentive Plan (the “Plan”). The Plan was approved by the Company’s shareholders at an annual meeting of shareholders held on April 24, 2026. The number of shares available under the Plan includes 4,697,275 shares of Common Stock reserved, but not issued under the Chemours Company 2017 Equity and Incentive Plan.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of this Registration Statement is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of the Registration Statement on Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the Plan covered by this Registration Statement as required by Rule 428(b)(1).

     

    PART II

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

     

    The following documents, which have been filed by the Company with the Securities and Exchange Commission (the “Commission”), are incorporated herein by reference:

     

    1.
    The Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on February 24, 2026 (including information specifically incorporated by reference therein from the Company’s Definitive Proxy Statement filed with the Commission on March 10, 2026);

     

    2.
    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Commission on May 5, 2026;

     

    3.
    The Company’s Current Reports on Form 8-K, filed with the Commission on January 16, 2026, February 26, 2026, March 12, 2026, and April 30, 2026; and

     

    4.
    The Company’s description of Common Stock contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Commission on February 14, 2020, including any amendments or reports filed for the purpose of updating such description.

     

    All documents filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement (other than any such documents or portions thereof that are furnished under

    Item 2.02 or Item 7.01 of a Current Report on Form 8-K, unless otherwise indicated therein, including any exhibits included with such Items), prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Unless otherwise stated in the applicable reports, information furnished under Item 2.02 or

    7.01 of a Current Report on Form 8-K shall not be incorporated by reference.

     

    Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein or in any subsequently filed document which is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 4. DESCRIPTION OF SECURITIES.

     

    Not applicable.

     

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.

     

    Not applicable.

     

     

     


     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

     

    The Delaware General Corporation Law (the “DGCL”) authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties as directors, and our amended and restated certificate of incorporation includes such an exculpation provision. Under the provisions of our amended and restated certificate of incorporation and bylaws, each person who is or was one of our directors or officers shall be indemnified by us as of right to the full extent permitted by the DGCL.

     

    Under the DGCL, to the extent that a person is successful on the merits in defense of a suit or proceeding brought against him or her because that person is or was one of our directors or officers, he or she shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred in connection with such action. If unsuccessful in defense of a third-party civil suit or a criminal suit, or if such a suit is settled, that person shall be indemnified against both (i) expenses, including attorneys’ fees, and (ii) judgments, fines and amounts paid in settlement if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests and, with respect to any criminal action, had no reasonable cause to believe his or her conduct was unlawful. If unsuccessful in defense of a suit brought by or in our right, or if such suit is settled, that person shall be indemnified only against expenses, including attorneys’ fees, incurred in the defense or settlement of the suit if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that if he or she is adjudged to be liable for negligence or misconduct in the performance of his or her duty to us, he or she cannot be made whole even for expenses unless the court determines that he or she is fairly and reasonably entitled to indemnity for such expenses.

     

    Under our amended and restated certificate of incorporation and bylaws, the right to indemnification includes the right to be paid by us the expenses incurred in defending any action, suit or proceeding in advance of its final disposition, subject to the receipt by us of undertakings as may be legally defined. In any action by an indemnitee to enforce a right to indemnification or by us to recover advances made, the burden of proving that the indemnitee is not entitled to be indemnified is placed on us.

     

    The Company has entered into indemnification agreements with its current directors and officers. The indemnification agreements supplement the indemnification provisions applicable under our amended and restated certificate of incorporation and bylaws, and the DGCL.

     

    Among the terms and conditions of the indemnification agreements are provisions providing for director and officer indemnitees to be indemnified in the context of certain third-party proceedings and proceedings by or in the right of the Company. The agreements also provide for, under certain circumstances, indemnification against certain expenses to the extent an indemnitee is wholly or partly successful in a proceeding, and to the extent an indemnitee is a witness or otherwise asked to participate in a proceeding to which the indemnitee is not a party. Also, under certain conditions, the indemnification agreements provide for the advancement of certain expenses from the Company to an indemnitee.

     

    We maintain liability insurance for our directors and officers to provide protection where we cannot legally indemnify a director or officer and where a claim arises under the Employee Retirement Income Security Act of 1974 against a director or officer based on an alleged breach of fiduciary duty or other wrongful act and directors’ and officers’ liability insurance for our directors and officers.

     

    The foregoing is only a general summary of certain aspects of Delaware law and our amended and restated certificate of incorporation and bylaws dealing with indemnification of directors and officers and does not purport to be complete. It is qualified in its entirety by reference to the detailed provisions of those sections of the DGCL referenced above and our amended and restated certificate of incorporation and bylaws.

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

     

    Not applicable.

     

    ITEM 8. EXHIBITS.

     

    The list of exhibits is set forth under “Exhibit Index” at the end of this Registration Statement and is incorporated herein by reference.

     

    ITEM 9. UNDERTAKINGS.

    (a)
    The undersigned Registrant hereby undertakes:

     

    (1)
    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

     


     

    (i)
    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)
    To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and

     

    (iii)
    To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement.

     

    Provided, however, that the undertakings set forth in paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2)
    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)
    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, State of Delaware, on May 6, 2026.

     

    THE CHEMOURS COMPANY

     

    By: /s/ Shane Hostetter

    Shane Hostetter

    Senior Vice President,

    Chief Financial Officer

     

     


     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Shane Hostetter and Kristine M. Wellman, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462 of the Securities Act of 1933), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    /s/ Denise Dignam

    Chief Executive Officer

    May 6, 2026

    Denise Dignam

    (Principal Executive Officer)

     

    /s/ Shane Hostetter

    Chief Financial Officer

    May 6, 2026

    Shane Hostetter

    (Principal Financial Officer)

     

    /s/ David Will

    Corporate Controller

    May 6, 2026

    David Will

    (Principal Accounting Officer)

     

    /s/ Mary B. Cranston

    Director

    May 6, 2026

    Mary B. Cranston

     

     

    /s/ George R. Brokaw

    Director

    May 6, 2026

    George R. Brokaw

     

     

    /s/ Alister Cowan

    Director

    May 6, 2026

    Alister Cowan

     

     

    /s/ Pamela Fletcher

    Director

    May 6, 2026

    Pamela Fletcher

     

     

    /s/ Erin N. Kane

    Director

    May 6, 2026

    Erin N. Kane

     

     

    /s/ Joseph D. Kava

    Director

    May 6, 2026

    Joseph D. Kava

     

     

    /s/ Sean D. Keohane

    Director

    May 6, 2026

    Sean D. Keohane

     

     

     

    /s/ Courtney R. Mather

    Director

    May 6, 2026

    Courtney R. Mather

     

     

    /s/ Livingston Satterthwaite

    Director

    May 6, 2026

    Livingston Satterthwaite

     

     

    /s/ Leslie M. Turner

    Director

    May 6, 2026

    Leslie M. Turner

     

     

     

     


     

     

     

     

    EXHIBIT INDEX

     

    Exhibit

    Number

    Description

    4.1

    Company’s Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 1, 2015).

    4.2

    Company’s Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on July 1, 2015).

    4.3

    The Chemours Company 2026 Equity and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on April 30, 2026).

    5.1

    Opinion of Goodwin Procter LLP.*

    23.1

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.*

    23.2

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).*

    24.1

    Power of Attorney (included on signature page).*

    107

    Filing Fee Table.*

     

    * Filed herewith.

     

     


    Get the next $CC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CC

    DatePrice TargetRatingAnalyst
    3/27/2025$19.00Neutral → Outperform
    Mizuho
    1/28/2025$27.00Buy
    Truist
    7/9/2024$28.00 → $30.00Neutral → Buy
    UBS
    6/7/2024$25.00Neutral
    Mizuho
    4/9/2024$19.00 → $34.00Underperform → Outperform
    BMO Capital Markets
    3/5/2024$37.00 → $21.00Buy → Neutral
    UBS
    2/29/2024$45.00 → $19.00Outperform → Underperform
    BMO Capital Markets
    12/1/2023$28.00 → $40.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $CC
    SEC Filings

    View All

    SEC Form SD filed by Chemours Company

    SD - Chemours Co (0001627223) (Filer)

    5/27/26 4:40:02 PM ET
    $CC
    Major Chemicals
    Industrials

    SEC Form S-8 filed by Chemours Company

    S-8 - Chemours Co (0001627223) (Filer)

    5/6/26 7:00:30 AM ET
    $CC
    Major Chemicals
    Industrials

    SEC Form 10-Q filed by Chemours Company

    10-Q - Chemours Co (0001627223) (Filer)

    5/5/26 5:04:45 PM ET
    $CC
    Major Chemicals
    Industrials

    $CC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cranston Mary B was granted 7,182 shares, increasing direct ownership by 7% to 106,830 units (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    5/8/26 4:15:22 PM ET
    $CC
    Major Chemicals
    Industrials

    Director Turner Leslie M was granted 7,182 shares, increasing direct ownership by 41% to 24,603 units (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    5/8/26 4:15:19 PM ET
    $CC
    Major Chemicals
    Industrials

    Director Kane Erin N was granted 7,182 shares, increasing direct ownership by 11% to 74,063 units (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    5/8/26 4:15:09 PM ET
    $CC
    Major Chemicals
    Industrials

    $CC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chemours Announces Dates for First Quarter 2026 Earnings Release and Webcast Conference Call

    WILMINGTON, Del., April 21, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE:CC) today announced that the Company expects to issue its first quarter 2026 financial results after market on Tuesday, May 5, 2026.The Company expects to hold its conference call to discuss its first quarter 2026 financial results at 8:00 a.m. Eastern Time on Wednesday, May 6, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.Conference Call: Please visit investors.chemours.

    4/21/26 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials

    The Chemours Company Announces Completion of Private Offering of $700,000,000 Aggregate Principal Amount of 7.875% Senior Unsecured Notes Due 2034

    WILMINGTON, Del., March 12, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE:CC) today announced it completed its previously announced private offering of $700,000,000 in aggregate principal amount of 7.875% senior unsecured notes due 2034 (the "Notes") that was exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The Notes are Chemours' senior unsecured obligations and are guaranteed by one of its subsidiaries.Chemours used the net proceeds from the offering, together with cash on hand, to fund the redemption of $188,000,000 aggregate principal amount of its 5.750% senior notes due 2028 for an aggregate redemption price of app

    3/12/26 5:00:00 PM ET
    $CC
    Major Chemicals
    Industrials

    The Chemours Company Announces Upsizing and Pricing of Private Offering of $700,000,000 of 7.875% Senior Notes Due 2034

    WILMINGTON, Del., Feb. 26, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC) today announced the pricing of its previously announced private offering of $700,000,000 aggregate principal amount of new 7.875% senior notes due 2034 (the "Notes"). The offering size was increased from the previously announced offering size of $600,000,000 aggregate principal amount of Notes. The Notes will bear interest at 7.875% per annum and mature on March 15, 2034. Interest on the Notes will be payable semi-annually on March 15 and September 15 of each year, beginning on September 15, 2026. The Notes will be senior unsecured obligations of Chemours and will be guaranteed by certain of its subsid

    2/26/26 4:39:00 PM ET
    $CC
    Major Chemicals
    Industrials

    $CC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Dignam Denise bought $49,060 worth of shares (4,068 units at $12.06) (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    8/12/25 5:12:16 PM ET
    $CC
    Major Chemicals
    Industrials

    Officer Gumpel Damian bought $201,376 worth of shares (21,222 units at $9.49), increasing direct ownership by 19% to 131,701 units (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    6/4/25 8:32:18 PM ET
    $CC
    Major Chemicals
    Industrials

    Chief Financial Officer Hostetter Shane bought $50,196 worth of shares (4,450 units at $11.28), increasing direct ownership by 8% to 59,694 units (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    5/21/25 5:13:57 PM ET
    $CC
    Major Chemicals
    Industrials

    $CC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chemours upgraded by Mizuho with a new price target

    Mizuho upgraded Chemours from Neutral to Outperform and set a new price target of $19.00

    3/27/25 8:05:02 AM ET
    $CC
    Major Chemicals
    Industrials

    Truist initiated coverage on Chemours with a new price target

    Truist initiated coverage of Chemours with a rating of Buy and set a new price target of $27.00

    1/28/25 7:09:50 AM ET
    $CC
    Major Chemicals
    Industrials

    Chemours upgraded by UBS with a new price target

    UBS upgraded Chemours from Neutral to Buy and set a new price target of $30.00 from $28.00 previously

    7/9/24 8:13:51 AM ET
    $CC
    Major Chemicals
    Industrials

    $CC
    Leadership Updates

    Live Leadership Updates

    View All

    Chemours Appoints Michael Foley as President of Titanium Technologies; Announces Departure of Damián Gumpel

    The Chemours Company ("Chemours") (NYSE:CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, today announced the appointment of Michael Foley as President of Chemours Titanium Technologies (TT), effective February 2026. Foley succeeds Damián Gumpel, who is departing the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204540269/en/Chemours appoints Michael Foley as President of Titanium Technologies Chemours thanks Mr. Gumpel for his contributions and wishes him well in his future endeavors. This transition reflects C

    12/4/25 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials

    Chemours Appoints Matthew Conti as Chief Human Resources Officer

    Seasoned HR executive supports Chemours' Pathway to Thrive strategy The Chemours Company (Chemours) (NYSE:CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (TSS), Titanium Technologies (TT), and Advanced Performance Materials (APM), today announced the appointment of Matthew Conti as Chief Human Resources Officer (CHRO), effective June 2. His appointment follows an extensive external search to identify a leader who will drive Chemours' people and culture strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612880421/en/Chemours appoints Matthew Conti as Chief Human Resource

    6/12/25 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials

    Chemours Appoints Industry Vet Nathan Blom as Vice President of Liquid Cooling Growth Portfolio

    The Chemours Company ("Chemours") (NYSE:CC), a global chemistry company, announced the appointment of Nathan Blom as Vice President of its liquid cooling portfolio, effective June 9, 2025. With Blom's wealth of technology and data center experience, his addition reinforces Chemours' commitment to driving near- and long-term growth in the liquid cooling market. Bringing over two decades of experience in executive leadership, business transformation, and go-to-market strategy across the technology and data center infrastructure sectors, Blom is a strong addition to Chemours leadership. The appointment supports the company's "Pathway to Thrive" strategy, with liquid cooling representing a ke

    6/10/25 6:45:00 AM ET
    $CC
    Major Chemicals
    Industrials

    $CC
    Financials

    Live finance-specific insights

    View All

    Chemours Announces Dates for First Quarter 2026 Earnings Release and Webcast Conference Call

    WILMINGTON, Del., April 21, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE:CC) today announced that the Company expects to issue its first quarter 2026 financial results after market on Tuesday, May 5, 2026.The Company expects to hold its conference call to discuss its first quarter 2026 financial results at 8:00 a.m. Eastern Time on Wednesday, May 6, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.Conference Call: Please visit investors.chemours.

    4/21/26 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials

    Chemours Announces First Quarter Dividend

    WILMINGTON, Del., Feb. 17, 2026 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE:CC) today announced that the Board of Directors of Chemours declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the first quarter of 2026. The dividend will be paid on March 13, 2026, to stockholders of record as of the close of business on February 27, 2026.About The Chemours CompanyThe Chemours Company (NYSE:CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through ou

    2/17/26 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials

    Chemours Announces Dates for Fourth Quarter 2025 Earnings Release and Webcast Conference Call

    WILMINGTON, Del., Feb. 4, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE:CC) today announced that the Company expects to issue its fourth quarter 2025 financial results after market on Thursday, February 19, 2026. The Company expects to hold its conference call to discuss its fourth quarter 2025 financial results at 8:00 a.m. Eastern Time on Friday, February 20, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of

    2/4/26 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials

    $CC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Chemours Company

    SC 13G/A - Chemours Co (0001627223) (Subject)

    11/12/24 9:55:16 AM ET
    $CC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Chemours Company (Amendment)

    SC 13G/A - Chemours Co (0001627223) (Subject)

    2/9/24 8:50:19 AM ET
    $CC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Chemours Company (Amendment)

    SC 13G/A - Chemours Co (0001627223) (Subject)

    1/24/24 9:46:44 AM ET
    $CC
    Major Chemicals
    Industrials